Ad is loading...
FSMAX
Price
$97.47
Change
+$1.63 (+1.70%)
Updated
Nov 22 closing price
PGRRX
Price
$50.44
Change
+$0.68 (+1.37%)
Updated
Nov 22 closing price
Ad is loading...

FSMAX vs PGRRX

Header iconFSMAX vs PGRRX Comparison
Open Charts FSMAX vs PGRRXBanner chart's image
Fidelity Extended Market Index
Price$97.47
Change+$1.63 (+1.70%)
VolumeN/A
CapitalizationN/A
Pioneer Select Mid Cap Growth R
Price$50.44
Change+$0.68 (+1.37%)
VolumeN/A
CapitalizationN/A
FSMAX vs PGRRX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSMAX vs. PGRRX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSMAX is a Buy and PGRRX is a Buy.

FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 40B vs. PGRRX (1.59B). FSMAX pays higher dividends than PGRRX: FSMAX (1.10) vs PGRRX (0.00). FSMAX was incepted earlier than PGRRX: FSMAX (13 years) vs PGRRX (31 years). PGRRX is a more actively managed with annual turnover of: 72.00 vs. FSMAX (18.00). FSMAX (0) and PGRRX (0) have matching initial minimum investment requirements. PGRRX (41.37) and FSMAX (40.44) have marching annual gain over last year. FSMAX return over 5 years is better than : 59.28 vs. PGRRX (19.58).
FSMAXPGRRXFSMAX / PGRRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years31 years-
Gain YTD24.86530.10183%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets40B1.59B2,522%
Annual Yield % from dividends1.100.00-
Returns for 1 year40.4441.3798%
Returns for 3 years10.11-9.77-104%
Returns for 5 years59.2819.58303%
Returns for 10 years88.8239.38226%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CORT57.541.62
+2.90%
Corcept Therapeutics
XPEL45.730.88
+1.96%
XPEL
MCO480.663.59
+0.75%
Moody's Corp
ORGO4.050.03
+0.75%
Organogenesis Holdings
ELTX4.93-0.19
-3.71%
Elicio Therapeutics